Clinical trials: Schizophrenic Psychoses
Schizophrenia, Cognitive Impairment
Functional Magnetic Resonance Imaging Study in Schizophrenia Patients and Correlation With Cognitive Impairments
1. Comparison of functional activity at different brain areas related to different cognitive domains e.g. Memory, visuospatial abilities, executive functions, attention, concentration, language, orientation in schizophrenia to…
- Trial name
- NCT06471179
- Testing
- Functional MRI
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Assiut University
Schizophrenia
Cognitive Remediation Method by Rhythmic, Vocal and Embodied Musical Learning for Stabilized Schizophrenic Patients
ARCoS is a pilot study evaluating the feasibility and preliminary effects of a method of cognitive remediation by a Rhythmic, Vocal and Embodied Musical Learning for a population of stabilized schizophrenic patients.
- Trial name
- ARCoS (NCT05124470)
- Testing
- cognitive remediation by musical training sessions
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Toulouse
Schizophrenia
12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
There has been evidence that ziprasidone is efficacious in decreasing the magnitude of both positive and negative symptoms of schizophrenia, and also effective in the treatment of depressive symptoms.
- Trial name
- NCT00159757
- Testing
- ziprazidone
- Where
- 8 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
First Episode Psychosis
Socially Inappropriate Behaviour in People With First Episode Psychosis: A Caregivers' Perspective
Social impairment is one of the core symptoms in first episode psychosis (FEP). Despite negative symptoms and social cognition impairment found in patient suffering from FEP, clinicians occasionally identified socially…
- Trial name
- NCT03501160
- Testing
- Face-to face semi-structured in-depth interview
- Where
- 2 sites in Hong Kong
- Volunteers
- 8 people
- Sponsor
- Chinese University of Hong Kong
Schizophrenia
A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting
The purpose of this study to evaluate safety, tolerability, treatment outcomes, appropriate use and pattern of paliperidone palmitate usage in participants with schizophrenia in the hospital setting.
- Trial name
- HOSPIPalm (NCT01926912)
- Testing
- No intervention
- Where
- 39 sites in Belgium, Bulgaria and 6 more
- Volunteers
- 371 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia
SPECT Study With SB-773812 In Schizophrenic Patients
This study is being conducted in 2 groups of schizophrenic patients: in group 1 the relationship between the dopaminergic D2 receptor occupancy (D2 RO ) and serotoninergic 5HT2A receptor occupancy at stable plasma concentration…
- Trial name
- NCT00269035
- Testing
- SB773812, Risperidone
- Where
- 6 sites in Spain
- Volunteers
- 95 people
- Sponsor
- GlaxoSmithKline
Schizophrenia
Study of Electrophysiological Markers Related to the Cognitive and Affective Processes Behind Empathic Behaviour in Schizophrenic Spectrum Disorder
Disorders of social cognition, and empathy more specifically, are at the heart of schizophrenic pathology in that they are strongly linked to the social handicap of patients.
- Trial name
- SchizoEmp (NCT04278339)
- Testing
- Evoked Related Potentials
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Schizophrenic Psychoses
Sustained Attention Abilities in Schizophrenia
Schizophrenia is a psychiatric pathology, which concerns around 1% of adult population. It is characterized by clinical symptoms combining positive and negative symptoms and thinking disorganization.
- Trial name
- ACCRAS (NCT02388607)
- Testing
- measurements
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Schizophrenia
Subjective Well Being of Schizophrenic Patients in Greece
Non-interventional study aiming to provide data on the subjective effects of antipsychotic medication assessing subjective well-being and global functioning of patients with Schizophrenia under antipsychotic medication.
- Trial name
- AURA (NCT00857064)
- Where
- 24 sites in Greece
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
The purpose of this study is to evaluate epidemiological characteristics of patients that experience relapse and need an admission in psychiatric acute units across Spain.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00399334
- Testing
- antipsychotic medications
- Volunteers
- 1,607 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia
A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode
The purpose of this study is to evaluate the outcome of medication discontinuation, the safety and effectiveness of re-initiating risperidone long acting injection (RLAI) in case of relapse (the return of a medical problem) of…
- Trial name
- NCT00378092
- Testing
- Oral risperidone, Risperidone Long-Acting Injection (RLAI)
- Where
- South Africa
- Volunteers
- 33 people
- Sponsor
- Janssen Cilag N.V./S.A.
Schizophrenia, Substance Use Disorders
The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients
The lifetime of substance use disorders in schizophrenia is close to 50%. Substance abuse in schizophrenia is associated with negative consequences.
- Trial name
- NCT00295412
- Testing
- quetiapine (drug)
- Where
- Canada
- Sponsor
- Université de Montréal
Schizophrenia, Schizophrenic Disorders
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
The purpose of this open-label study is to evaluate the long-term (6-month) safety and tolerability of extended-release paliperidone, an atypical antipsychotic, given in flexible dosages to adolescents with schizophrenia.
- Conditions
- Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
- Trial name
- NCT00488319
- Testing
- Paliperidone ER
- Where
- 53 sites in United States, Belgium and 9 more
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Psychotic Disorders
Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone
To assess the effect of risperidone 2 mg daily (QD) on the differential sensitivity of 2 spatial working memory tests (the GMLT and MDR) in non-agitated, drug-naive patients suffering from first-episode…
- Trial name
- NCT00174200
- Testing
- Risperidone 2 mg
- Where
- 3 sites in Canada, Russia
- Volunteers
- 20 people
- Sponsor
- Pfizer
Dental Diseases, Schizophrenia
Oral Status of Patients Suffering From SCHIZophrenia Followed at Charles Perrens Hospital
The aim of the study is to describe the oral health status of patients suffering from schizophrenia and schizoaffective disorders in a psychiatric institute in France.
- Trial name
- BUCCOSCHIZ (NCT04191200)
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Centre Hospitalier Charles Perrens, Bordeaux
Schizophrenia, Psychotic Disorder
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia
The purpose of the study is to evaluate the effectiveness and safety of different doses of risperidone (an antipsychotic medication) compared with a fixed 10-mg dose of a standard antipsychotic, haloperidol, in patients with…
- Trial name
- NCT00249119
- Testing
- risperidone
- Volunteers
- 1,579 people
- Sponsor
- Janssen, LP
Schizophrenia, Schizoaffective Disorder
Assessment of Efficacy of a Psychological Therapy in Inpatients With a Schizophrenic Psychosis
This randomised three-arm study aims to evaluate the efficacy and feasibility of a cognitive behavioral therapy (INT-Integrated Neurocognitive Therapy for Schizophrenia Patients) in the treatment of schizophrenia patients in an…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- CBTSZ (NCT03316664)
- Testing
- Integrated Neurocognitive Therapy (INT), Integrated Psychological Therapy (IPT), COGPACK
- Where
- Switzerland
- Volunteers
- 82 people
- Sponsor
- Psychiatric University Hospital, Zurich
Psychosis;Schizophrenic
Seven-step Phenomenological Psychotherapy for Self-disorder - a Pilot Study
The goal of this clinical pilot study is to learn how adults with schizophrenia or other non-affective psychotic disorders or psychosis risk syndromes experience a novel psychotherapeutic treatment for self-disorders.
- Trial name
- SSPP-SD-p (NCT06597864)
- Testing
- Seven-step phenomenological psychotherapy for self-disorders
- Where
- 2 sites in Norway
- Volunteers
- 8 people
- Sponsor
- Oslo University Hospital
Schizophrenia
Oxytocin Add on Study for Stable Schizophrenic Patients
The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms despite being on adequate treatment with…
- Trial name
- Oxytocin (NCT00506909)
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- David Feifel
Schizophrenias, Psychoses
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
Adjuvant N-methyl-D-aspartic acid (NMDA)-enhancing agents, such as GlyT-1 inhibitors and NMDA-glycine site agonists have been demonstrated to be beneficial for chronic schizophrenia patients.
- Conditions
- Schizophrenias, Psychoses, Psychotic Disorders, Schizophrenic Disorders
- Trial name
- NCT00960219
- Testing
- D-amino acid oxidase inhibition (DAAOI-1)
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- China Medical University Hospital